BiPar Sciences Overview

  • Founded
  • 2002
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 20
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $539M
Latest Deal Amount

BiPar Sciences General Information

Description

Developer of tumor-selective drugs designed to target multiple cancer types including therapy-resistant and difficult-to-treat cancers. The company offers a poly ribose polymerase inhibitor for metastatic triple-negative breast cancer, ovarian cancer, and other malignancies, a follow-on inhibitor candidate for pancreatic cancer, and an iodothyronine program with anti-tubulin properties, thereby enabling healthcare providers to enhance the anti-tumor effects of chemotherapy.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • 400 Oyster Point Boulevard
  • Suite 200
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BiPar Sciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 15-Apr-2009 $539M 0000 00000 Completed Generating Revenue
5. Later Stage VC (Series C) 12-Jan-2009 0000 0000 Completed Generating Revenue
4. Later Stage VC (Series B1) 30-Dec-2008 000 0000 000.00 Completed Generating Revenue
3. Later Stage VC (Series B) 26-Feb-2007 0000 0000 0000 Completed Generating Revenue
2. Debt - General 14-Jun-2006 $5M $18M Completed Startup
1. Early Stage VC (Series A) 20-Dec-2004 $13M $13M 000.00 Completed Startup
To view BiPar Sciences’s complete valuation and funding history, request access »

BiPar Sciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B1 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 29,893,629 $0.001000 $0.03 $0.44 $0.44 1x $0.44 21.71%
To view BiPar Sciences’s complete cap table history, request access »

BiPar Sciences Patents

BiPar Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20120245117-A1 Methods of treating squamous cell lung cancer with 4-iodo-3-nitrobenzamide in combination with gemcitabine and carboplatin Abandoned 04-Mar-2011 0000000000
AU-2011282223-A1 Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents Withdrawn 19-Jul-2010 00000000000
US-20130274281-A1 Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan Abandoned 19-Jul-2010 00000000000 0
JP-2013531068-A Method for treating breast cancer using 4-iodo-3-nitrobenzamide in combination with an antitumor agent Abandoned 19-Jul-2010 00000000000
JP-2013531069-A Method for treating metastatic breast cancer using 4-iodo-3-nitrobenzamide and irinotecan Abandoned 19-Jul-2010 A61K31/4745

BiPar Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BiPar Sciences Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Asset Management Ventures Venture Capital Minority 000 0000 000000 0
Canaan Partners Venture Capital Minority 000 0000 000000 0
Domain Associates Venture Capital Minority 000 0000 000000 0
Lighthouse Capital Partners Venture Capital Minority 000 0000 000000 0
Michael Weickert Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »